ArticleNature biotechnology2020
Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy.
Open access · greenAbstract read
In one paragraph
Article in Nature biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 83 citations in OpenAlex.
- TechBio 3.0 closes the drug discovery loop with multimodal AI and generative chemistry.npj drug discovery · 2026Review
- Intratumoral T cell activation kills tumors regardless of T cell specificity.Nature immunology · 2026Article
- Design and therapeutic rationale of antibody-peptide conjugates: insights from maridebart cafraglutide (AMG133) and emerging applications.Antibody therapeutics · 2026Review
- Oncolytic virotherapy mobilizes tumor-resident, granzyme B-producing bystander CD4Molecular therapy. Oncology · 2026Article
- Oncolytic virotherapy potentiates chemo-PD-1 immunotherapy by engaging chemo-resistant bystander CD8Journal for immunotherapy of cancer · 2026Article
- Article
- Epstein-barr virus and multiple sclerosis: from pathogenesis and diagnosis to EBV-specific T cell therapy and gene-targeted therapeutics.Journal of applied genetics · 2026Review
- Safety signals and CMV-related events reported during letermovir therapy: a FAERS database study.Frontiers in pharmacology · 2026Article
- Review
- Increasing the odds: antibody-mediated delivery of two distinct immunogenic T-cell epitopes with one antibody.Oncoimmunology · 2025Article
- A Bioorthogonal and Programmable Bacterial Delivery System for Spatiotemporally Targeted Therapy of Solid Tumors.Exploration (Beijing, China) · 2025Article
- Bacterial Foreignization Nanosystem Elicits Multi-Phenotypic T Cells for Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Sensitizing solid tumors to CAR-mediated cytotoxicity by lipid nanoparticle delivery of synthetic antigens.Nature cancer · 2025Article
- LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment.Nature communications · 2025Article
- A Universal Strategy of Anti-Tumor mRNA Vaccine by Harnessing "Off-the-Shelf" Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cytomegalovirus Reactivation Is Associated With Lower Rates of Hepatocellular Carcinoma Recurrence After Liver Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Lrp10 suppresses IL7R limiting CD8 T cell homeostatic expansion and anti-tumor immunity.EMBO reports · 2024Article
- IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy.Cell reports. Medicine · 2024Article
- Intratumor injection of BCG Ag85A high-affinity peptides enhanced anti-tumor efficacy in PPD-positive melanoma.Cancer immunology, immunotherapy : CII · 2024Article
- Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine.NPJ vaccines · 2024Article
Corrections and comments
- Commented on by
Authors and funding
29 authors at 3 institutions in 2 countries.
David G MillarMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.
Rakesh R RamjiawanSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.
Kosuke KawaguchiSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.
Nisha GuptaSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.
Jiang ChenSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.
Songfa ZhangMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.
Takashi NojiriSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.
William W HoSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1755-833X
Shuichi AokiSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.
Keehoon JungSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.
Ivy ChenSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.
Feng ShiMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.
James M HeatherMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1783-5181
Kohei ShigetaSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1596-4200
Laura T MortonMedical Research Council Centre for Immune Regulation and Clinical Immunology Service, School of Immunity and Infection, College of Medicine and Dental Sciences, University of Birmingham, Birmingham, UK.
Sean SepulvedaMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.
Li WanMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.
Ricky JosephMedical Research Council Centre for Immune Regulation and Clinical Immunology Service, School of Immunity and Infection, College of Medicine and Dental Sciences, University of Birmingham, Birmingham, UK.
Eleanor MinogueMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.
Ashok KhatriMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.
Aditya BardiaMassachusetts General Hospital, Boston, MA, USA.
Leif W EllisenMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.
Ryan B CorcoranMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8173-5778
Aaron N HataMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA.
Sara I PaiDivision of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Rakesh K JainSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7571-3548
Dai FukumuraSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9505-4444
Dan G DudaSteele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA.
Mark CobboldMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA, USA. mcobbold@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-8931-4142
Harvard University · USImmune Regulation (United Kingdom) · GBMassachusetts General Hospital · US
Funding
Vascular Normalization: Rolse of Perivascular CellsP01CA080124 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2000 to 2016
$35.0MStrategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI MEMPEL, THORSTEN ROMAN · 2019 to 2023
$8.4MDissecting Pediatric Brain Tumor Microenvironment to Improve TreatmentR35CA197743 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2015 to 2020
$5.7MReprogramming PDAC tumor microenvironment to improve immunotherapyU01CA224348 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUCHER, YVES, JAIN, RAKESH K. · 2017 to 2021
$2.9MReengineering obesity-induced abnormal microenvironment to improve PDAC treatmentR01CA208205 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI, JAIN, RAKESH K. · 2017 to 2020
$2.2MDevelopment, Characterization & Commercialization of a Viably Frozen, Patient-Inclusive Hepatocellular Carcinoma Tumor BankR41CA213678 · NCI · WOODLAND PHARMACEUTICALS, LLC · PI BRIGGS, MICHAEL, DUDA, DAN GABRIEL · 2017 to 2017
$300kNCI NIH HHS P01 CA080124NCI NIH HHS P01 CA240239NCI NIH HHS R01 CA208205NCI NIH HHS R35 CA197743NCI NIH HHS R41 CA213678NCI NIH HHS U01 CA224348NIAID NIH HHS HHSN272201300006C
Abstract
Several cancer immunotherapy approaches, such as immune checkpoint blockade and adoptive T-cell therapy, boost T-cell activity against the tumor, but these strategies are not effective in the absence of T cells specific for displayed tumor antigens. Here we outline an immunotherapy in which endogenous T cells specific for a noncancer antigen are retargeted to attack tumors. The approach relies on the use of antibody-peptide epitope conjugates (APECs) to deliver suitable antigens to the tumor surface for presention by HLA-I. To retarget cytomegalovirus (CMV)-specific CD8
Indexed as
AnimalsAntibodiesCD8-Positive T-LymphocytesCell Line, TumorCytomegalovirusEpitopes, T-LymphocyteHistocompatibility Antigens Class IHumansImmunoconjugatesImmunomodulationImmunotherapy, AdoptiveLymphocyte ActivationMatrix MetalloproteinasesMiceNeoplasmsAntibodiesEpitopes, T-LymphocyteHistocompatibility Antigens Class IImmunoconjugatesMatrix Metalloproteinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.